A detailed history of Swiss National Bank transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Swiss National Bank holds 40,700 shares of JANX stock, worth $2.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,700
Previous 31,800 27.99%
Holding current value
$2.21 Million
Previous $1.2 Million 42.36%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$35.12 - $64.78 $312,568 - $576,542
8,900 Added 27.99%
40,700 $1.7 Million
Q4 2023

Feb 06, 2024

BUY
$5.85 - $11.7 $52,650 - $105,300
9,000 Added 39.47%
31,800 $341,000
Q2 2023

Aug 09, 2023

SELL
$11.08 - $15.92 $46,536 - $66,864
-4,200 Reduced 15.56%
22,800 $270,000
Q1 2023

May 10, 2023

BUY
$11.25 - $22.21 $303,750 - $599,670
27,000 New
27,000 $326,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.27B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.